CEDARS-SINAI MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $170.2M
- Transactions
- 9,900
- Companies
- 40
- Average per transaction
- $17,193
Who reported the payments
| Siemens Medical Solutions USA, Inc. | $23,883,878 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $20,187,179 |
| Merck | $19,808,797 |
| Edwards Lifesciences | $12,104,760 |
| Boston Scientific | $10,295,369 |
| Pfizer | $6,858,790 |
| E.r. Squibb & Sons, L.L.C. | $4,135,702 |
| Eli Lilly | $4,049,174 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,866,184 |
| AstraZeneca | $3,253,855 |
| Amgen | $3,014,251 |
| Genentech, Inc. | $2,981,471 |
| Janssen Research & Development, LLC | $2,832,702 |
| AbbVie | $2,693,148 |
| Abbott | $2,388,766 |
| Brahms GmbH | $1,967,139 |
| Bausch Health US, LLC | $1,651,975 |
| Bristol Myers Squibb | $1,574,700 |
| Gilead | $1,556,189 |
| Alnylam Pharmaceuticals Inc. | $1,178,325 |
| Alkermes, Inc. | $1,174,170 |
| CSL Behring | $1,151,507 |
| Medtronic | $1,079,139 |
| Regeneron | $978,651 |
| Biogen | $924,358 |
| Olympus Corporation Of The Americas | $855,794 |
| Vertex | $852,003 |
| Jenavalve Technology, Inc. | $816,412 |
| Genmab A/s | $773,828 |
| Teva Pharmaceuticals USA, Inc. | $759,309 |
| KARL Storz Endoscopy-america | $740,448 |
| Cardiovascular Systems Inc. | $701,050 |
| Otsuka Pharmaceutical Co., Ltd. | $697,145 |
| Seagen Inc. | $686,069 |
| Boehringer Ingelheim | $675,069 |
| Intuitive Surgical | $658,192 |
| Roche Diagnostics Operations, Inc. | $649,766 |
| Blueprint Medicines Corporation | $638,854 |
| Stryker | $625,816 |
| Novartis | $619,217 |